Prognostic Significance of Metabolic Tumor Volume Measured by 18F-FDG PET/CT in Operable Primary Breast Cancer

Kim, Jahae; Yoo, Su Woong; Kang, Sae-Ryung; Cho, Sang-Geon; Oh, Jong-Ryool; Chong, Ari; Min, Jung‐Joon; Bom, Hee‐Seung; Yoon, Junghan; Song, Ho‐Chun

doi:10.1007/s13139-012-0161-9

Cited by 44 publications

(29 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PET/CT is also useful in evaluating treatment response and recurrence [2]. Parameters of 18F-FDG PET/CT, including maximum standardized uptake value (SUV max ) and metabolic tumor volume (MTV), are considered to be prognostic factors for survival and predictors of treatment response [3,4,5,6,7]. Tumor heterogeneity measured by 18F-FDG PET/CT has been emphasized in various malignancies.…”

Section: Introductionmentioning

confidence: 99%

Tumor Heterogeneity Assessed by 18F-FDG PET/CT Is Not Significantly Associated with Nodal Metastasis in Breast Cancer Patients

et al. 2015

View full text Add to dashboard Cite

Introduction: The purpose of this study was to evaluate the association of tumor heterogeneity as assessed by positron emission tomography/computed tomography (PET/CT) with pathological factors of breast cancer, and the prediction of nodal metastasis through tumor heterogeneity. Methods: From January 2013 to December 2013, 102 patients with invasive ductal carcinoma of the breast were enrolled into this study. [¹⁸F]Fluorodeoxyglucose PET/CT was performed before surgery. The metabolic tumor volume (MTV) of each lesion was calculated and a series of standardized uptake value (SUV) thresholds (e.g. 40%, 50%, 60%, 70%, and 80% of SUVmax) was obtained. A threshold-volume (dV/dT) curve was acquired by plotting thresholds to MTV values automatically calculated with these thresholds. Tumor heterogeneity was calculated from the slope of the threshold-volume curve and defined as heterogeneity factor (HF). Results: HF differed significantly according to T stage (p < 0.0001), N stage (p = 0.0131) and American Joint Committee on Cancer (AJCC) stage (p = 0.0006). Among the pathological parameters, dermal lymphatic involvement (p = 0.0039) showed the significant correlations with HF. Lymphovascular invasion (p = 0.0005) was the only independent factor for predicting nodal metastasis. Conclusions: Tumor heterogeneity measured by 18F-FDG PET/CT is significantly associated with dermal lymphatic involvement. However, PET might not be able to predict nodal metastasis in breast cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Tumor Heterogeneity Assessed by 18F-FDG PET/CT Is Not Significantly Associated with Nodal Metastasis in Breast Cancer Patients

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Recently, Groheux et al [15] reported that TLG is superior to SUVmax as a predictor of outcome in patients with ER-positive/HER2-negative breast cancer. In addition, only one study has considered the role of MTV as a prognostic factor in breast cancer patients [6]. However, there are no studies that evaluated the correlation among WB semiquantitative PET/CT data, DFS and OS in patients with stage II/III breast cancer.…”

Section: Discussionmentioning

confidence: 99%

“…16 is a good predictor of disease progression and overall survival (OS). The usefulness of other measures, such as metabolic tumour volume (MTV) and total lesion glycolysis (TLG), for determining the aggressiveness of tumours and for predicting treatment response has been evaluated; however, although preliminary findings are encouraging, associations between these measures and prognosis have not been found consistently [6,7]. The aim of our study was to investigate whether SUVmax, MTV and TLG, and whole-body (WB) SUVmax, WB MTV and WB TLG can be considered prognostic factors predicting disease-free survival (DFS) and OS in patients with stage II/III breast cancer.…”

Section: Introductionmentioning

confidence: 99%

“…In contrast to our study, Satoh et al considered a small inhomogeneous (stage I/II/III/IV) population of 24 patients at initial staging of disease. Moreover, Kim et al[6] considered a group of patients with LABC who underwent PET/CT with FDG before NAC. The authors calculated the SUVmax and MTVof the primary tumours and lymph nodes, and the sum of the highest MTV in both primary tumour and lymph nodes (called T MTV).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment?

Evangelista

Cervino

Ghiotto

et al. 2015

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…Growing evidence suggests that MTV and TLG may have prognostic value in several solid tumors . However, the use of these volumetric metabolic parameters in the prognosis of BC remains limited and the results are somewhat controversial, and criteria for these parameters have yet to be established …”

Section: Introductionmentioning

confidence: 99%

Risk stratification in patients with advanced‐stage breast cancer by pretreatment [¹⁸F]FDG PET/CT

Chen

Ibrahim

Yan

et al. 2015

Cancer

View full text Add to dashboard Cite

BACKGROUND:The objective of the current study was to investigate the prognostic value of pretreatment [ Pretreatment PET/CT scans from 240 consecutive patients with American Joint Committee on Cancer stage III or stage IV BC were analyzed retrospectively. Clinicopathological factors and metabolic parameters of the primary tumor including maximum standardized uptake value (SUV max ), metabolic tumor volume, and total lesion glycolysis (TLG) with a range of thresholds were compared to predict progression-free survival (PFS) and overall survival (OS) using a time-dependent receiver operating characteristic curve and Cox proportional hazards regression analyses. RESULTS: SUV max with a cutoff value of 6.0, TLG 30% with a cutoff value of 158 g, and phenotype associated with PFS and OS were analyzed using multivariate analysis. The mean TLG 30% of primary tumors for patients with stage III and stage IV disease was 405 g and 750 g (P 5 .010), respectively. Patients with triple-negative breast cancer or a TLG 30% >158 g or with both were categorized as being at high risk, and those with non-triple-negative breast cancer and a primary tumor with a TLG 30% 158 g were defined as low risk. The 5-year PFS rates for stage III disease among patients with low-risk versus high-risk BC were 85% and 67.5%, respectively. For patients with stage IV disease, the 5-year PFS rates were 45% and 9%, respectively, for patients with low-risk versus high-risk disease. Patients with stage III and high-risk BC had OS rates that were similar to those for patients with stage IV and low-risk BC (P 5 .552). CONCLUSIONS: The TLG 30% from pretreatment PET/CT was found to independently correlate with survival outcomes and appears to be able to effectively stratify both patients with stage III and those with stage IV BC. Cancer 2015;121:3965-74.

show abstract

Prognostic Significance of Metabolic Tumor Volume Measured by 18F-FDG PET/CT in Operable Primary Breast Cancer

Abstract: PET indices seem to be useful in the preoperative evaluation of prognosis in patients with operable primary breast cancer. NSUV, NMTV and TMTV might be considerable factors associated with patient outcome in operable breast cancer.

Cited by 44 publications

References 23 publications

Tumor Heterogeneity Assessed by 18F-FDG PET/CT Is Not Significantly Associated with Nodal Metastasis in Breast Cancer Patients

Tumor Heterogeneity Assessed by 18F-FDG PET/CT Is Not Significantly Associated with Nodal Metastasis in Breast Cancer Patients

Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment?

Risk stratification in patients with advanced‐stage breast cancer by pretreatment [¹⁸F]FDG PET/CT

Contact Info

Product

Resources

About

Prognostic Significance of Metabolic Tumor Volume Measured by 18F-FDG PET/CT in Operable Primary Breast Cancer

Abstract: PET indices seem to be useful in the preoperative evaluation of prognosis in patients with operable primary breast cancer. NSUV, NMTV and TMTV might be considerable factors associated with patient outcome in operable breast cancer.

Cited by 44 publications

References 23 publications

Tumor Heterogeneity Assessed by 18F-FDG PET/CT Is Not Significantly Associated with Nodal Metastasis in Breast Cancer Patients

Tumor Heterogeneity Assessed by 18F-FDG PET/CT Is Not Significantly Associated with Nodal Metastasis in Breast Cancer Patients

Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment?

Risk stratification in patients with advanced‐stage breast cancer by pretreatment [18F]FDG PET/CT

Contact Info

Product

Resources

About

Risk stratification in patients with advanced‐stage breast cancer by pretreatment [¹⁸F]FDG PET/CT